Nasal Potential Difference in Cystic Fibrosis considering Severe CFTR Mutations
Table 4
Association of nasal potential difference between cystic fibrosis patients and healthy subjects.
NPD variables
Groups
Mean
Standard deviation
Standard error
Confidence interval
Minimum
Maximum
value
5%
95%
Finger (mV)
A
10
−31.40
27.452
8.681
−51.04
−11.76
−57
37
0.004
0.020
B
5
−39.40
7.956
3.558
−49.28
−29.52
−52
−31
C
21
−20.10
16.078
3.508
−27.41
−12.78
−41
36
Total
36
−25.92
20.090
3.348
−32.71
−19.12
−57
37
PDMax (mV)
A
10
−2.40
18.075
5.716
−15.33
10.53
−42
21
0.111
0.555
B
5
5.60
14.064
6.290
−11.86
23.06
−12
23
C
21
10.52
11.378
2.483
5.34
15.70
−14
28
Total
36
6.25
14.594
2.432
1.31
11.19
−42
28
Δamiloride (mV)
A
10
12.30
18.379
5.812
−0.85
25.45
−20
42
0.611
1
B
5
5.20
15.353
6.866
−13.86
24.26
−10
27
C
21
9.52
10.482
2.287
4.75
14.29
−5
45
Total
36
9.69
13.469
2.245
5.14
14.25
−20
45
Δchloride-free + isoproterenol
A
10
0.750
7.270
2.299
−4.450
5.950
−12.0
12.5
0.016
0.08
B
5
−1.800
5.805
2.596
−9.008
5.408
−7.0
7.0
C
21
−7.881
8.235
1.7971
−11.630
−4.132
−26.5
6.0
Total
36
−4.639
8.482
1.4137
−7.509
−1.769
−26.5
12.5
Wilschanski index
A
10
1.112
0.627
0.198
0.664
1.561
0.535
2.718
0.005
0.025
B
5
0.610
0.274
0.123
0.269
0.950
0.223
0.883
C
21
0.435
0.362
0.081
0.267
0.603
0
1.051
Total
36
0.648
0.526
0.088
0.469
0.826
0
2.718
= number of patients; CF = cystic fibrosis; mV = millivolts; PDMax = maximum NPD; Wilschanski index = .
#Kruskal-Wallis statistical test. The positive value is in italic. The value was corrected using the Bonferroni test. Five analyses were performed on the same sample group.
